Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

This month’s featured Healio Exclusive on the “evidence-based and ethically sound” definition of long COVID is particularly ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

Commerzbank Aktiengesellschaft FI reduced its stake in Deere & Company by 9.1% in the first quarter. The firm sold 2,490 ...